英国药品定价谈判破裂 制药行业警告：将危及未来在英投资

Group 1 - The UK government and major pharmaceutical companies ended negotiations on drug pricing without reaching an agreement, raising concerns about future investments in the sector [1] - The UK Health Secretary announced that the government's proposal to increase drug spending while reducing contributions from pharmaceutical companies to the NHS was unprecedented [1] - The stalemate highlights the deteriorating relationship between the Labour government and large pharmaceutical firms, conflicting with the government's commitment to boost investment and productivity [1][2] Group 2 - The main point of contention in the negotiations was the rebate mechanism, which requires pharmaceutical companies to refund the government if NHS drug spending exceeds a set limit [1] - The UK's rebate mechanism, known as the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), demands a 23% rebate on sales exceeding budget growth limits, significantly higher than in other European countries [1][2] - The pharmaceutical industry is advocating for a reduction of the rebate percentage to single digits and has expressed concerns over the slow pace of broader reforms [2] Group 3 - The failure to reach an agreement may exacerbate concerns about the declining attractiveness of the UK market for life sciences investments, with companies feeling frustrated over pricing mechanisms that do not keep pace with inflation [3] - AstraZeneca's CEO criticized the UK's business environment, indicating that the company has halted plans to establish a vaccine factory in the UK due to these challenges [3] - The ongoing drug pricing dispute serves as a warning signal, as the UK has historically benefited from significant discounts on NHS-provided drugs, which has enhanced its appeal in other markets [3]